On the morning of September 20, Investors' Experience Sharing Forum was held successfully. Well-known investors, experts and scholars participated in this event, sharing their personal experience and opinions with representatives from top leading investment banks, institutions and innovative pharmaceutical enterprises, including Morgan Stanley, J.P. Morgan, CICC, YuanMing Capital, Sequoia Capital China, GTJA Investment Group, Prudence Investment, BeiGene, etc. The topics involved the role of capital and fund in the market of innovative drugs, the influence on investment brought by the change of policies, new investment trends in pharmaceutical industry and innovative pharmaceutical enterprises, as well as other major issues and concerns.

Plenary Meeting of Investors' Experience Sharing Forum

Panel Discussion I in Investors' Experience Sharing Forum

From left to right:

Moderator: Kevin LI, Managing Partner, LYZZ Capital Advisors

ZHU Jinqiao, Chairman & President, Efung Investment Management Enterprise

ZHANG Jiang, Managing Partner, Ping’an Ventures

CHEN Bing, Partner, Highlight Capital, Stephen LIN, Partner, Lilly Asia Ventures

Panel Discussion II in Investors' Experience Sharing Forum

 From left to right:

Moderator: James LI, CEO, JW Therapeutics

Xiaobo LU, Partner, Sequoia Capital China

Kevin CHEN, Founding Partner, Biotrack Capital

Kevin YUAN, Founder, Jianxin Capital

Cheng XING, Managing Partner, Sherpa Venture Capital

Panel Discussion III in Investors' Experience Sharing Forum

From left to right:

Moderator: Tina YU, Managing Partner of YuanMing Capital, CEO of Mevion Medical Systems

Park PU, Vice Chairman of China Investment Banking, J.P. Morgan Securities (Asia Pacific) Limited

Samuel THONG, Senior Advisor, Morgan Stanley Asia Limited

ZHOU Hao, Partner, Prudence Investment Management (Hong Kong) Limited

Cathy ZHANG, Managing Director, CICC

Investors' Experience Sharing Forum is closely correlated with the theme of 2018 CBIIC. Senior experts, investors, partners and entrepreneurs shared personal experiences on R&D, business and investment, and discussed on topics including the trends and evaluation of investment in healthcare industry, the relationship between investors and entrepreneurs, which brought a broaden commercial horizon and a profound reflection for participants, and built a platform of direct communication between pharmaceutical innovation and investment.

Roadshow speakers surrounded by investors at the conference

In the afternoon, the Cross-Border M&A Forum, a newly-established forum in 2018 CBIIC, focused on the development of global resource-integrated enterprises. Invited speakers analyzed the concerning problems that enterprises might encounter during the whole process of merging from different perspective, including enterprises, capital market, and investment, providing strategies for the participants.

Panel Discussion I in Cross-Border M&A Forum

From left to right:

Moderator: LI Yishi, Principle, HaoYue Capital

XIAO Long’an, GM of Shenzhen Branch, AVIC Trust Co., Ltd.

ZENG Xiaojun, Chief Managing Partner, GTJA Investment Group

Sean LU, President, CMF

SU Hua, Partner of Life Science and Healthcare, Ernst & Young (China) Advisory Limited

LI Qian, Vice President, Ping An Bank Finance SBU of Healthcare, Culture &Tourism Industries

Panel Discussion II in Cross-Border M&A Forum

From left to right:

Moderator: Sammy JIANG, Vice President (Strategy, BD) of Luye Pharma Group

LIU Hao, Founder & CEO of HaoYue Capital

YUAN Bing, Founder & CEO of JUVA Medical Technology Co., Ltd.

Charles CHAU, Partner of Jones Day (Hong Kong Office)

Cecila WANG, Director of Bocom International (Shanghai) Ltd.

Focusing on promoting innovation in pharmaceutical industry, PhIRDA will continue to facilitate pharmaceutical innovation industry and financing institutions, and pay more attention on hot topics about investment, making a more splendid and international CBIIC next year. Let us meet at the 2019 CBIIC in Suzhou on September 21-23 again.

Plenary Meeting of Cross-Border M&A Forum